AA
NGNE icon

ALPS Advisors’s Neurogene NGNE Stock Holding History

ALPS Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$504K Buy
16,040
+3,434
+27% +$94.5K ﹤0.01% 979
2026
Q1 		$254K Sell
12,606
-115
-0.9% -$2.23K ﹤0.01% 982
2025
Q4 		$262K Buy
+12,721
New +$317K ﹤0.01% 951
2018
Q4 		– Sell
-2,076
Closed -$122K – 915
2018
Q3 		$122K Buy
2,076
+373
+22% +$22K ﹤0.01% 936
2018
Q2 		$90K Buy
1,703
+129
+8% +$33.6K ﹤0.01% 918
2018
Q1 		$443K Buy
1,574
+274
+21% +$75.7K ﹤0.01% 743
2017
Q4 		$306K Buy
1,300
+144
+12% +$33.7K ﹤0.01% 734
2017
Q3 		$328K Buy
1,156
+101
+10% +$29K ﹤0.01% 720
2017
Q2 		$297K Buy
1,055
+47
+5% +$13.4K ﹤0.01% 720
2017
Q1 		$336K Sell
1,008
-117
-10% -$41.1K ﹤0.01% 677
2016
Q4 		$372K Buy
+1,125
New +$302K ﹤0.01% 637
2016
Q2 		– Sell
-968
Closed -$171K – 633
2016
Q1 		$171K Sell
968
-166
-15% -$32.3K ﹤0.01% 607
2015
Q4 		$283K Buy
+1,134
New +$298K ﹤0.01% 654

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

ALPS Advisors's NGNE Position: Q2 2026 in Review

ALPS Advisors increased its Neurogene (NGNE) stake by 27% in Q2 2026, buying an estimated $94.5K and bringing the position to 16,040 shares worth $504K. The position accounts for ﹤0.01% of the portfolio, ranked #979.

ALPS Advisors first reported a position in NGNE in Q4 2015 and has held it in 13 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • ALPS Advisors held 16,040 shares of Neurogene worth $504K as of Q2 2026.
  • ALPS Advisors bought 3,434 Neurogene shares in Q2 2026, an estimated $94.5K.
  • Neurogene made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #979 holding.
  • ALPS Advisors first reported a position in Neurogene in Q4 2015 and has held it in 13 quarters since.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.